Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial
0
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: This study aimed to evaluate whether fluvoxamine reduces clinical deterioration in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), and to identify risk factors for clinical deterioration in patients admitted to a community treatment center (CTC). Materials and methods: A randomized, placebo-controlled trial was conducted in a CTC, in Seoul, Korea from January 15, 2021, to February 19, 2021. Symptomatic adult patients with positive results of severe acute respiratory syndrome coronavirus 2 real time-polymerase chain reaction within 3 days of randomization were assigned at random to receive 100 mg of fluvoxamine or placebo twice daily for 10 days. The primary outcome was clinical deterioration defined by any of the following criteria: oxygen requirement to keep oxygen saturation over 94.0%, aggravation of pneumonia with dyspnea, or World Health Organization clinical progression scale 4 or greater. Results: Of 52 randomized participants [median (interquartile range) age, 53.5 (43.3 - 60.0) years; 31 (60.0%) men], 44 (85.0%) completed the trial. Clinical deterioration occurred in 2 of 26 patients in each group (P >0.99). There were no serious adverse events in either group. Clinical deterioration occurred in 15 (6.0%) of 271 patients admitted to the CTC, and all of them were transferred to a hospital. In multivariate analysis, age between 55 and 64, fever and pneumonia at admission were independent risk factors for clinical deterioration. Conclusion: In this study of adult patients with symptomatic COVID-19 who were admitted to the CTC, there was no significant differences in clinical deterioration between patients treated with fluvoxamine and placebo (ClinicalTrials.gov Identifier: NCT04711863).
Abstract
Background: This study aimed to evaluate whether fluvoxamine reduces clinical deterioration in adult patients with mild to moderate coronavirus disease 2019 (COVID-19), and to identify risk factors for clinical deterioration in patients admitted to a community treatment center (CTC). Materials and methods: A randomized, placebo-controlled trial was conducted in a CTC, in Seoul, Korea from January 15, 2021, to February 19, 2021. Symptomatic adult patients with positive results of severe acute respiratory syndrome coronavirus 2 real time-polymerase chain reaction within 3 days of randomization were assigned at random to receive 100 mg of fluvoxamine or placebo twice daily for 10 days. The primary outcome was clinical deterioration defined by any of the following criteria: oxygen requirement to keep oxygen saturation over 94.0%, aggravation of pneumonia with dyspnea, or World Health Organization clinical progression scale 4 or greater. Results: Of 52 randomized participants [median (interquartile range) age, 53.5 (43.3 - 60.0) years; 31 (60.0%) men], 44 (85.0%) completed the trial. Clinical deterioration occurred in 2 of 26 patients in each group (P >0.99). There were no serious adverse events in either group. Clinical deterioration occurred in 15 (6.0%) of 271 patients admitted to the CTC, and all of them were transferred to a hospital. In multivariate analysis, age between 55 and 64, fever and pneumonia at admission were independent risk factors for clinical deterioration. Conclusion: In this study of adult patients with symptomatic COVID-19 who were admitted to the CTC, there was no significant differences in clinical deterioration between patients treated with fluvoxamine and placebo (ClinicalTrials.gov Identifier: NCT04711863).
참고문헌 (28)
- Ahmad FB, "Provisional mortality data-United States, 2020", MMWR Morb Mortal Wkly Rep, 70, pp.519~522 (2021)
- Peck Kyong Ran, "Collaborative Response to COVID-19 Pandemic, and Development of Treatment Guidelines", Infection and Chemotherapy, 53(1), pp.151~154 (2021), 대한감염학회[DOI]
- RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with Covid-19", N Engl J Med, 384, pp.693~704 (2021)
- Salama C, "Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia", N Engl J Med, 384, pp.20~30 (2021)
- Beigel JH, "Remdesivir for the treatment of Covid-19-Final Report", N Engl J Med, 383, pp.1813~1826 (2020)
- Park HY, "Presenting characteristics and clinical outcome of patients with COVID-19 in South Korea : A nationwide retrospective observational study", Lancet Reg Health West Pac, 5, pp.100061~ (2020)
- Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
- Lenze EJ, "Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19 : A randomized clinical trial", JAMA, 324, pp.2292~2300 (2020)
- Hashimoto K, "Repurposing of CNS drugs to treat COVID-19 infection : targeting the sigma-1 receptor", Eur Arch Psychiatry Clin Neurosci, 271, pp.249~258 (2021)
- Almási N, "Sigma-1 receptor engages an anti-inflammatory and antioxidant feedback loop mediated by peroxiredoxin in experimental colitis", Antioxidants(Basel), 9, pp.1081~ (2020)
- Hoertel N, "Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19 : results from an observational study", Mol Psychiatry, 26, pp.5199~5212 (2021)
- Zarandi PK, "SARS-CoV-2 : From the pathogenesis to potential anti-viral treatments", Biomed Pharmacother, 137, pp.111352~ (2021)
- Kim S, "Discovering spatiotemporal patterns of COVID-19 pandemic in South Korea", Sci Rep, 11, pp.24470~ (2021)
- 김미선, "Clinical Characteristics and Risk Factors for Severe Disease of Coronavirus Disease 2019 in a Low Case Fatality Rate Region in Korea", Infection and Chemotherapy, 53(4), pp.718~729 (2021), 대한감염학회[DOI]
- Kang E, "Operating protocols of a community treatment center for isolation of patients with coronavirus disease, South Korea", Emerg Infect Dis, 26, pp.2329~2337 (2020)
- Peong Gang Park, "Out-of-Hospital Cohort Treatment of Coronavirus Disease 2019 Patients with Mild Symptoms in Korea: an Experience from a Single Community Treatment Center", Journal of Korean Medical Science, 35(13), pp.1~6 (2020), 대한의학회[DOI]
- World Medical Association, "World Medical Association Declaration of Helsinki : ethical principles for medical research involving human subjects", JAMA, 310, pp.2191~2194 (2013)
- CDC COVID-19 Response Team, "COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019(COVID-19)-United States, February 12-March 16, 2020", MMWR Morb Mortal Wkly Rep, 69, pp.343~346 (2020)
- "COVID-19 treatment guidelines. Coronavirus disease 2019(COVID-19) treatment guidelines"[URL]
- WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, "A minimal common outcome measure set for COVID-19 clinical research", Lancet Infect Dis, 20, pp.e192~e197 (2020)
- Lee Sun Young, "Operation and Management of Seoul Metropolitan City Community Treatment Center for Mild Condition COVID-19 Patients", Journal of Korean Medical Science, 35(40), pp.1~13 (2020), 대한의학회[DOI]
- "WHO COVID-19 Dashboard"[URL]
- Seftel D, "Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19", Open Forum Infect Dis, 8, pp.ofab050~ (2021)
- Reis G, "Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19 : the TOGETHER randomised, platform clinical trial", Lancet Glob Health, 10, pp.e42~51 (2022)
- Feng Z, "Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics", Nat Commun, 11, pp.4968~ (2020)
- Gandhi RT, "Mild or moderate Covid-19", N Engl J Med, 383, pp.1757~1766 (2020)
- Lee YH, "Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea", Emerg Infect Dis, 26, pp.2346~2352 (2020)
- Undurraga EA, "COVID-19 case fatality risk by age and gender in a high testing setting in Latin America : Chile, March-August 2020", Infect Dis Poverty, 10, pp.11~ (2021)